[HTML][HTML] PLK1, a potential target for cancer therapy
Z Liu, Q Sun, X Wang - Translational oncology, 2017 - Elsevier
Abstract Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …
Plk1 inhibitors in cancer therapy: from laboratory to clinics
Abstract Polo-like kinase 1 (Plk1) overexpression has been shown to occur in a wide range
of tumors, prompting research and development of Plk1 inhibitors as a means of cancer …
of tumors, prompting research and development of Plk1 inhibitors as a means of cancer …
Present and future perspective on PLK1 inhibition in cancer treatment
M Chiappa, S Petrella, G Damia, M Broggini… - Frontiers in …, 2022 - frontiersin.org
Polo-like kinase 1 (PLK1) is the principle member of the well conserved serine/threonine
kinase family. PLK1 has a key role in the progression of mitosis and recent evidence …
kinase family. PLK1 has a key role in the progression of mitosis and recent evidence …
Endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity may be therapeutically targeted by natural and chemical compounds: A review
F Yarmohammadi, R Rezaee, AW Haye… - Pharmacological …, 2021 - Elsevier
Doxorubicin (DOX) is a chemotherapeutic agent with marked, dose-dependent cardiotoxicity
that leads to tachycardia, atrial and ventricular arrhythmia, and irreversible heart failure …
that leads to tachycardia, atrial and ventricular arrhythmia, and irreversible heart failure …
Inhibition of the PLK1‐coupled cell cycle machinery overcomes resistance to oxaliplatin in colorectal cancer
Z Yu, P Deng, Y Chen, S Liu, J Chen, Z Yang… - Advanced …, 2021 - Wiley Online Library
Dysregulation of the cell cycle machinery leads to genomic instability and is a hallmark of
cancer associated with chemoresistance and poor prognosis in colorectal cancer (CRC) …
cancer associated with chemoresistance and poor prognosis in colorectal cancer (CRC) …
[HTML][HTML] Strategies to tackle RAS-mutated metastatic colorectal cancer
The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are
identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC) …
identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC) …
Recent advances and new strategies in targeting Plk1 for anticancer therapy
Polo-like kinase 1 (Plk1) plays key roles in regulating mitotic processes that are crucial for
cellular proliferation. Overexpression of Plk1 is tightly associated with the development of …
cellular proliferation. Overexpression of Plk1 is tightly associated with the development of …
Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications
Abstract Polo-like kinase 1 (PLK1) is a conserved mitotic serine-threonine protein kinase,
functions as a regulatory protein, and is involved in the progression of the mitotic cycle. It …
functions as a regulatory protein, and is involved in the progression of the mitotic cycle. It …
The importance of Ras in drug resistance in cancer
FM Healy, IA Prior, DJ MacEwan - British journal of …, 2022 - Wiley Online Library
In this review, we analyse the impact of oncogenic Ras mutations in mediating cancer drug
resistance and the progress made in the abrogation of this resistance, through …
resistance and the progress made in the abrogation of this resistance, through …
Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways
Aims Rigosertib (RGS) is a PI3K inhibitor that exerts protective effects against tumor
progression and cancer-related inflammation. This study was aimed to explore the …
progression and cancer-related inflammation. This study was aimed to explore the …